p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling  by Budanov, Andrei V. & Karin, Michael
p53 Target Genes Sestrin1 and Sestrin2
Connect Genotoxic Stress
and mTOR Signaling
Andrei V. Budanov1 and Michael Karin1,*
1Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine,
University of California, San Diego, 9500 Gilman Drive, MC0723, La Jolla, CA 92093, USA
*Correspondence: karinoffice@ucsd.edu
DOI 10.1016/j.cell.2008.06.028SUMMARY
The tumor suppressor p53 is activated upon geno-
toxic and oxidative stress and in turn inhibits cell
proliferation and growth through induction of specific
target genes. Cell growth is positively regulated by
mTOR, whose activity is inhibited by the TSC1:TSC2
complex. Although genotoxic stress has been sug-
gested to inhibit mTOR via p53-mediated activation
of mTOR inhibitors, the precise mechanism of this
link was unknown. We now demonstrate that the
products of two p53 target genes, Sestrin1 and Ses-
trin2, activate the AMP-responsive protein kinase
(AMPK) and target it to phosphorylate TSC2 and
stimulate its GAP activity, thereby inhibiting mTOR.
Correspondingly, Sestrin2-deficient mice fail to in-
hibit mTOR signaling upon genotoxic challenge.
Sestrin1 and Sestrin2 therefore provide an important
link between genotoxic stress, p53 and the mTOR
signaling pathway.
INTRODUCTION
The major tumor suppressor p53 is a stress-activated transcrip-
tion factor that can either inhibit cell proliferation or induce
apoptotic cell death (Levine, 1997). The different functions of
p53 are mediated through numerous target genes, such as
p21Waf1, which serves as a cell-cycle inhibitor (Levine, 1997). In
addition to cell proliferation, p53 also inhibits cell growth, a func-
tion that is important for preventing the wasteful buildup of pro-
teins and other cellular building blocks during periods of stress
(Vousden and Lane, 2007). Cell growth is regulated by the target
of rapamycin (TOR), an evolutionary conserved protein (280 kDa)
that belongs to the phosphatidylinositol kinase-related kinase
(PIKK) subfamily (Wullschleger et al., 2006). The mammalian
TOR protein (mTOR) forms two distinct signaling complexes,
called mTORC1 and mTORC2. The mTORC1 complex, which,
in addition to mTOR, consists of raptor, PRAS40, and mLST8,
is responsible for control of cell growth and protein synthesis
(Guertin and Sabatini, 2007; Yang and Guan, 2007). ThemTORC2 complex, consisting of mTOR, rictor, Sin1, PROTOR,
and mLST8, controls the actin cytoskeleton and cell spreading
(Astrinidis et al., 2002; Sarbassov et al., 2004; Yang and Guan,
2007). Rapamycin, an inhibitor of cell growth, rapidly inhibits
mTORC1 through interaction with FKBP12, but after a while, it
may also inhibit mTORC2 (Sarbassov et al., 2006). mTORC1
activity is positively regulated by growth factors through the insu-
lin/insulin-like growth factor (IGF1)-phosphoinositide-30 kinase
(PI3K)-AKT pathway, the Wnt-GSK3 pathway, and the ERK-
RSK kinase cascade (Wullschleger et al., 2006; Yang and
Guan, 2007). mTORC1 activity is inhibited by adverse environ-
mental and metabolic conditions, including nutrient limitation,
hypoxia, and DNA damage (Corradetti and Guan, 2006; Inoki
et al., 2003a).
The positive and negative control of mTORC1 activity is
exerted through the TSC1:TSC2 complex, whose TSC2 subunit
serves as a GAP for the small GTPase Rheb, which activates
mTOR (Corradetti and Guan, 2006; Hay and Sonenberg,
2004; Wullschleger et al., 2006). TSC2 activity is regulated by
several kinases, including AKT, ERK, RSK, and AMP-activated
protein kinase (AMPK) (Corradetti and Guan, 2006; Kwiatkow-
ski and Manning, 2005). Genotoxic stress was suggested to in-
hibit mTORC1 activity through p53-dependent upregulation of
negative regulators such as PTEN, TSC2, and AMPKb1 (Feng
et al., 2007). p53 also increases the phosphorylation of the
AMPKa subunit, leading to AMPK activation (Feng et al.,
2005). However, the precise physiological mechanism by which
p53 activates AMPK and inhibits mTOR is not established.
Two recently described p53 target genes genes are Sestrin1
(Sesn1)/PA26 and Sestrin2(Sesn2)/Hi95 (Budanov et al., 2002;
Peeters et al., 2003; Velasco-Miguel et al., 1999). Previous stud-
ies have shown that Sesn1 and Sesn2, whose expression is
induced upon DNA damage and oxidative stress, may have a cy-
toprotective function based on regeneration of overoxidized per-
oxiredoxins (Budanov et al., 2004). We now demonstrate that
Sesn1 and Sesn2 are negative regulators of mTOR signaling
and that they execute this redox-independent function through
activation of AMPK and TSC2 phosphorylation. We also provide
in vivo evidence for the functional importance of Sesn2 in inhibi-
tion of mTOR signaling in mice treated with a p53-activating
alkylating agent. Hence, Sesn1 and Sesn2 link genotoxic stress,
p53, and mTOR signaling.Cell 134, 451–460, August 8, 2008 ª2008 Elsevier Inc. 451
RESULTS
Sestrins Inhibit mTOR-Dependent S6K and 4E-BP1
Phosphorylation
To examine whether Sestrins regulate mTOR, we used p70S6K
phosphorylation (Burnett et al., 1998; Corradetti and Guan,
2006) as a readout. p70S6K activation can in turn be determined
by phosphorylation of ribosomal S6 protein at S235/236 (Dufner
and Thomas, 1999; Pende et al., 2004). We cotransfected
HEK293 cells with HA-tagged p70S6K together with Sesn1-
Flag (F), Sesn2F, both TSC1F and TSC2F, or GFP expression
vectors. HA-p70S6K was immunoprecipitated, and its phos-
phorylation was examined with phospho-specific antibodies.
Ectopic expression of either Sesn1F or Sesn2F dramatically
inhibited T389 p70S6K phosphorylation, as did TSC1F:TSC2F
overexpression (Figure 1A). Although Sesn1F was expressed
less efficiently than Sesn2F, its inhibitory effect was pronounced
(Figure 1A). However, when expressed at similar levels, no sub-
stantial differences in the inhibitory activity of the two Sestrins
were observed (Figure S1A available online). To examine regula-
tion of endogenous mTOR and p70S6K, we generated MCF7-tet
OFF cells with doxycycline-regulated Sesn2F. To reduce possi-
ble toxicity due to Sesn2 overexpression, we infected cells with
low-titer virus and selected cells on puromycin as described
(Budanov et al., 2002). After 24 hr of doxycycline removal,
Sesn2F was expressed, and considerable inhibition of p70S6K
and S6 phosphorylation was observed (Figure 1B). This inhibi-
tory effect of Sesn2 was seen as early as 6 hr after doxycycline
withdrawal, when its expression was barely detectible
(Figure S1B). Another important target of mTOR is 4E-BP1,
which is phosphorylated on many sites (Hay and Sonenberg,
2004). We examined 4E-BP1 phosphorylation using anti-phos-
pho-S65 antibodies, as well as changes in its electrophoretic
mobility (Guan et al., 2007). Sesn2 induction decreased the
abundance of the hyperphosphorylated g form of 4E-BP1 and
increased the abundance of the hypophosphorylated a form
(Figure 1B). Similar results were seen upon infection of cells
with lentiviral vectors expressing Sesn1 or Sesn2 (Figure S1C).
In an attempt to localize the protein domain responsible for
inhibition of mTOR, we expressed Sesn2 deletion mutants in
H1299 cells. Deletion of either the N- or C-terminal portions com-
pletely blocked the ability of Sesn2 to inhibit mTOR signaling
(Figure S1D). mTOR is redox sensitive (Dames et al., 2005;
Sarbassov and Sabatini, 2005), and the Sestrins were reported
to be involved in redox-mediated reactivation of peroxiredoxins
(Budanov et al., 2004). However, a redox-inactive Sesn2(C125S)
mutant (Budanov et al., 2004) was as effective as WT Sesn2 in
inhibition of p70S6K and S6 phosphorylation (Figure 1C).
Expression of peroxiredoxin 1 (Prx1) had no effect on p70S6K
and S6 phosphorylation.
Nonphosphorylated 4E-BP1 binds and sequesters eIF-4E,
thereby inhibiting formation of the eIF-4F complex involved in ini-
tiation of Cap-dependent translation of a subset of mRNAs that
include cyclin D1 and c-Myc (Thomas, 2006; Averous and Proud,
2006; Mamane et al., 2004). Phosphorylated 4E-BP1 cannot in-
teract with eIF-4E and does not inhibit eIF-4F formation (Richter
and Sonenberg, 2005). To determine whether Sesn1 and Sesn2
modulate the interaction between 4E-BP1 and eIF-4E, we452 Cell 134, 451–460, August 8, 2008 ª2008 Elsevier Inc.isolated Cap-binding complexes with 7-methyl-guanosine
(m7G)-RNA- Sepharose beads from control and doxycycline-
deprived MCF7-tet OFF Sesn2F cells. Expression of Sesn2F
induced 4E-BP1:eIF-4E complex formation as effectively as
rapamycin treatment (Figure 1D). Sesn2F induction inhibited
expression of both cyclin D1 and c-Myc but did not affect their
mRNA amounts (Figure 1E).
TSC2 Is Required for Sestrin-Mediated Inhibition
of mTOR Signaling
To elucidate how the Sestrins inhibit mTOR, we coexpressed
either Sesn2 or GFP with HA-p70S6K, and the transfected cells
Figure 1. Sesn1 and Sesn2 Inhibit mTOR Signaling
(A) Ectopic Sesn1, Sesn2, or TSC1:TSC2 expression decreases p70S6K phos-
phorylation. HEK293 cells were cotransfected with HA-p70S6K together with
Sesn1F, Sesn2F, TSC1F plus TSC2F, or GFP expression vectors. After 48 hr,
HA-p70S6K was immunoprecipitated (IP), and its phosphorylation was exam-
ined by immunoblotting. Sesn1 and Sesn2 and TSC1:TSC2 expression in total
lysates was examined by immunoblotting (IB).
(B) Induction of Sesn2 inhibits mTOR signaling. Sesn2F was induced in MCF7-
tet OFF Sesn2F cells by doxycycline (Dox) removal. Control cultures were left
with doxycycline. After 22 hr, rapamycin (Rapa; 20 ng/ml) was added to some
of the cultures. Cell lysates were prepared 2 hr later, and expression and phos-
phorylation of the indicated mTOR pathway components was examined by
immunoblotting.
(C) Sesn2 redox activity is not required for inhibition of mTOR signaling. H1299
cells were infected with WT or mutant Sesn2F-lentiviruses as well as GFP- and
Prx1-lentiviruses and analyzed for phosphorylation and expression of the
indicated proteins as above.
(D) Sesn2 increases association of 4E-BP1 and eIF-4E with m7G-RNA Cap
structures. Sesn2 was induced as in B and cell lysates were incubated with
m7G-Sepharose beads for 6 hr, and bead-bound proteins were examined by
immunoblotting (upper panel). Expression levels and phosphorylation state
of the indicated proteins in the total lysates were analyzed as in (B) (lower
panel).
(E) Sesn2 induction inhibits cyclin D1 and c-Myc protein expression but does
not affect their mRNAs. Sesn2F was induced by doxycycline withdrawal, and
expression of cyclin D1 and c-Myc was examined 24 hr later by immunoblot-
ting (IB). RNA from the same cells was analyzed by northern blotting (NB) with
cyclin D1 or c-Myc probes. 18S RNA was used as a loading control.
were treated with insulin to activate the PI3K-AKT-mTOR path-
way. We also cotransfected cells with constructs expressing
constitutively active H-Ras, myristoylated AKT (myr-AKT), or
Rheb, which upon overexpression is no longer inhibited by en-
dogenous TSC1:TSC2. Sesn2 inhibited p70S6K phosphoryla-
tion in all cases except when coexpressed with Rheb
(Figure 2A), suggesting that Sesn2 affects mTOR signaling
upstream of Rheb (Figure 2A).
To determine whether Sesn2 modulates Rheb GTP loading,
we induced its expression in MCF7-tet OFF cells that were la-
beled with 32P and immunoprecipitated endogenous Rheb.
Inhibition of p70S6K phosphorylation by Sesn2F in these cells
Figure 2. Sestrins Inhibit mTOR Signaling Upstream to the
TSC1:TSC2 Complex
(A) Rheb abrogates Sesn2-induced inhibition of p70S6K phosphorylation.
HEK293 cells were cotransfected with HA-p70S6K and either Sesn2 or GFP
plasmids together with either myristoylated (myr)-AKT, H-Ras or Rheb
constructs or were treated without (Con.) or with insulin for 1 hr as indicated.
HA-p70S6K was immunoprecipitated (IP) with anti-HA antibody, and its
phosphorylation was examined by immunoblotting. Total cell lysates were
immunoblotted (IB) with the indicated antibodies.
(B) Sesn2 expression decreases Rheb GTP loading. Sesn2 was induced in
MCF7-tet OFF Sesn2F cells for 24 hr, and cells were metabolically labeled
with 32P for 4 hr. Rheb was immunoprecipitated, and guanine nucleotides
were extracted, separated by thin-layer chromatography, autoradiographed,
and quantified by QuantityOne software. Rheb recovery was examined by
immunoblotting and used to normalize the calculated GTP/GDP ratio. The
values shown are averages ± SD of three experiments.
(C) TSC2 is required for downregulation of p70S6K phosphorylation by Sesn1
and Sesn2. Tsc2+/+ and Tsc2/ fibroblasts were cotransfected with
HA-p70S6K together with Sesn1, Sesn2, or GFP expression vectors. HA-
p70S6K was immunoprecipitated (IP), and its phosphorylation was examined
by immunoblotting. Sesn1 and Sesn2 expression in total lysates was exam-
ined by immunoblotting (IB). NS, nonspecific band.
(D) Inhibition of mTOR signaling by Sesn2 requires TSC2. MCF7-tet OFF
Sesn2F cells were infected with shTSC2- or shLuc-lentiviruses. After 48 hr,
Sesn2F was induced by doxycycline removal, and protein phosphorylation
and expression was examined 24 hr later.was confirmed by immunoblot analysis (Figure S2A). Rheb-
associated guanine nucleotides were extracted and separated
by thin-layer chromatography. Sesn2F expression induced a
2-fold decrease in the relative amount of Rheb-associated GTP
(Figure 2B). These results suggest that Sesn2 negatively
regulates Rheb GTP loading.
Rheb GTP loading is controlled by the TSC1:TSC2 complex
(Garami et al., 2003; Inoki et al., 2003b; Tee et al., 2003). To as-
sess the role of this complex in inhibition of mTOR by Sesn1 and
Sesn2, we used Tsc2+/+ and Tsc2/ cells. Whereas Sesn1 and
Sesn2 inhibited p70S6K phosphorylation in WT cells, they failed
to do so in TSC2-deficient cells (Figure 2C). To confirm the crit-
ical role of TSC1:TSC2 in the response to Sesn1 andSesn2 in hu-
man cancer cell lines, we knocked down TSC2 in both H1299
and MCF7-tet OFF Sesn2F cells. Downregulation of TSC2 com-
promised Sestrin-induced inhibition of p70S6K, S6, and 4E-BP1
phosphorylation (Figure 2D, Figure S2B).
AMPK Is Important for Sestrin-Induced mTOR Inhibition
To study whether AMPK is involved in negative regulation of
mTOR by Sesn1 and Sesn2, we examined phosphorylation of
AMPK and its target acetyl-CoA carboxylase (ACC) (Motoshima
et al., 2006). Expression of Sesn1 or Sesn2 strongly enhanced
AMPK phosphorylation and slightly increased ACC phosphory-
lation (Figure 3A, Figure S3A). In comparison to Sesn1 and
Sesn2 or campotecin treatment, activation of AMPK in response
to 2-deoxyglucose (2-DG) resulted in much stronger ACC phos-
phorylation (Figure S3B). We considered whether the Sestrins
activate AMPK through induction of metabolic stress by lowering
of cellular ATP. We measured cellular ATP after Sesn2F induc-
tion and found no difference from control cells (data not shown).
To further examine the role of AMPK in Sestrin-modulatedmTOR
inhibition, we used compound C, an AMPK inhibitor (Zhou et al.,
2001). Compound C prevented inhibition of p70S6K phosphory-
lation by Sesn2F (Figure 3B). To rule out nonspecific effects of
compound C, we knocked down AMPKa1, the major form of
Figure 3. Sestrins Inhibit p70S6K Phosphorylation via an AMPK-
Dependent Mechanism
(A) Sesn2 expression enhances AMPK phosphorylation. Sesn2F was induced
in MCF7-tet OFF Sesn2F cells, and phosphorylation of the indicated proteins
was examined 24 hr later.
(B) Compound C abrogates Sestrin-induced inhibition of p70S6K phosphory-
lation. Sesn2F was induced in MCF7-tet OFF Sesn2F cells in the presence of
compound C (CompC) or vehicle control (DMSO), and protein phosphorylation
was examined 24 hr later.
(C) Knockdown of AMPKa1 abrogates Sesn2 inhibition of p70S6K and S6
phosphorylation. MCF7-tet OFF Sesn2F cells were infected with shAMPKa1-
or shLuc-lentiviruses. Protein phosphorylation and expression were analyzed
by immunoblotting 72 hr after infection and 24 hr after doxycycline removal.Cell 134, 451–460, August 8, 2008 ª2008 Elsevier Inc. 453
AMPK in MCF7 cells (data not shown), and found that this also
prevented inhibition of p70S6K and S6 phosphorylation
(Figure 3C). Similar results were obtained with another shRNA
to AMPKa1 (data not shown).
Sestrins Interact with TSC1, TSC2, and AMPK
To determine whether the Sestrins can interact with TSC1,
TSC2, or AMPK, we expressed TSC1-Myc, TSC2-HA, and
AMPKa2-Myc together with Sesn2F in HEK293 cells. Immuno-
precipitation of Sesn2F resulted in coprecipitation of TSC1-
Myc, TSC2-HA, and AMPKa2Myc (Figure 4A). None of these
proteins was precipitated by the Flag antibody if they were coex-
pressed with GFP instead of Sesn2F. Reciprocal immunoprecip-
itation experiments confirmed the interaction of Sesn2 with
TSC1, TSC2, and AMPKa2 (Figure S4A). Similar results were
obtained with Sesn1 and AMPKa1 (Figures S4B and S4C). We
also performed immunoprecipitation experiments with Sesn2
mutants lacking the N-terminal (DN), C-terminal (DC), or middle
segments (DM) of the protein and found that the N-terminal seg-
ment was important for interaction with AMPKa2. However, all
three mutants retained interaction with the TSC1:TSC2 complex
(Figure S4D).
To study whether a complex containing Sesn2, TSC1, TSC2,
and AMPKcan form undermore physiological conditions, we im-
munoprecipitated lysates of MCF7-tet OFF Sesn2F or MCF7-tet
OFF GFP cells with the Flag antibody. The MCF7-tet OFF
Sesn2F cells were kept on low concentration of doxycycline to
achieve Sesn2F amounts similar to those seen in the same cells
after camptothecin treatment (Figure 4B). Under these condi-
tions, endogenous TSC1, TSC2, AMPKa1, and its phosphory-
lated form were coprecipitated along with Sesn2F (Figure 4B).
To obtain further biochemical evidence for a complex containing
TSC1, TSC2, AMPKa1, and Sesn2, we used gel filtration chro-
matography. TSC1, TSC2, AMPKa1, and Sesn2 coeluted in sev-
eral highmolecular weight fractions ranging from 0.4 to 1.13 106
Da (Figure 4C). Only a portion of the total Sesn2 or AMPKa1 pool
coeluted with the TSC1:TSC2 complex. The AMPK-activating
kinase LKB1 eluted as a low molecular weight protein and was
not present in the high molecular weight fractions (Figure 4C).
Because immunoprecipitation of endogenous Sesn2 with the
available antibody from a variety of cell lines failed to detect
the Sesn2:AMPK:TSC1:TSC2 complex, probably because of
low antibody affinity or low Sesn2 amounts, we repeated the
gel filtration experiment using extracts of livers isolated from
mice injected with the hepatocarcinogen diethylnitrosamine
(DEN; see below). As described above, a portion of Sesn2 eluted
in fractions ranging from 0.3 to 1.15 3 106 Da (data not shown).
We pooled these fractions and immunoprecipitated them with
the Sesn2 antibody. This resulted in coimmunoprecipitation of
AMPKa1, AMPKa2, TSC1, and TSC2 (Figure 4D).
Sestrins Activate AMPK and Enhance TSC2
Phosphorylation
To determine whether the Sestrins stimulate AMPK kinase activ-
ity, we coexpressed Flag-tagged AMPKa1 with either GFP, WT
Sesn2, or the Sesn2-DN deletion mutant, which cannot interact
with AMPK. The tagged AMPKa1 subunit was immunoprecipi-
tated, and the resulting immunecomplexwas assayed for its abil-454 Cell 134, 451–460, August 8, 2008 ª2008 Elsevier Inc.ity to phosphorylate the TSC1:TSC2 complex isolated from tran-
siently transfected HEK293 cells. Coexpression of WT Sesn2
strongly enhanced the ability of AMPK to phosphorylate TSC2
and undergo autophosphorylation (Figure 5A). No TSC1 phos-
phorylation was detected. The truncated Sesn2 protein had
only a marginal effect on AMPK kinase activity. We also exam-
ined the ability of Sesn2 to induce TSC1 or TSC2 phosphoryla-
tion in live cells by metabolic labeling. Expression of Sesn2 in
HEK293 cells resulted in a substantial increase in TSC2 phos-
phorylation (Figure 5B). No TSC1 phosphorylation could be
Figure 4. Sestrins Interact with TSC1:TSC2 and AMPK
(A) Coimmunoprecipitation of TSC1, TSC2, and AMPKa2 with Sesn2. HEK293
cells were cotransfected with Sesn2F or GFP expression vectors along with
tagged TSC1, TSC2, TSC1 plus TSC2, or AMPKa2 plasmids as indicated.
Sesn2F was immunoprecipitated with anti-Flag, and presence of the indicated
proteins in the immunecomplexes (IP) and total lysates (IB) was examined by
immunoblotting.
(B) Coimmunoprecipitation of endogenous TSC1, TSC2, and AMPKa1 with
Sesn2. Sesn2F or GFP were induced in MCF7-tet OFF Sesn2F or GFP cells
by incubation in low doxycycline concentration (0.01 mg/ml). After 24 hr, the
cells were lysed. Sesn2F was immunoprecipitated with anti-Flag, and pres-
ence of the indicated proteins in the immunoprecipitates (IP) and original
lysates (IB) was examined. For comparison, MCF7 cells were incubated with
camptothecin (Camp) for 12 hr to induce Sesn2 expression that was examined
by immunoblotting of the same amount of cell lysates as above.
(C) Sesn2 coelutes with TSC1, TSC2, and AMPKa in high molecular weight
fractions. Extracts of H1299 cells were separated on a Superdex 200 gel filtra-
tion column and analyzed by immunoblotting. The elution positions (in kDa) of
molecular weight standards are indicated at the top.
(D) Coimmunoprecipitation of TSC1, TSC2, and AMPKa with endogenous
Sesn2. Two-month-old WT male mice were injected with DEN (100 mg/kg).
After 24 hr, the liver was removed, homogenized, and filtered. The lysate
was separated by gel filtration as above, and the high molecular weight frac-
tions were combined and immunoprecipitated with anti-Sesn2 or control
anti-rabbit (Con.) IgG. Presence of the indicated proteins in the immunepreci-
pitates was analyzed by immunoblotting.
detected, and, as above, the truncated Sesn2-DN protein had
little stimulatory effect on TSC2 phosphorylation. We also com-
pared the phosphorylation of Sesn2-associated and Sesn2-
unassociated AMPKa1. As shown in Figure 5C, AMPKa1 that
was coprecipitated with Sesn2 was more intensely phosphory-
lated at residue T172 within its activation loop than AMPKa1
that was not coprecipitated with Sesn2. Collectively, these
results suggest that the Sestrins activate AMPK through direct
interaction and stimulate its kinase activity toward TSC2, which
is present in a complex with AMPK and Sesn1 and Sesn2.
Sestrins Play a Physiologically Important Role
in mTOR Regulation
To study the role of endogenous Sestrins inmTOR regulation, we
knocked down Sesn1 or Sesn2 using shRNA in H1299 cells
(Budanov et al., 2004). Silencing of Sesn1 had a marginal effect
in this cell line, whereas the knockdown of Sesn2 increased
phosphorylation of both p70S6K and S6 (Figure S6A). Two differ-
ent Sesn1 and Sesn2 shRNAs exerted similar effects (data not
shown). Becausewe suspected that Sesn1 does not significantly
contribute to mTOR regulation in the p53-negative H1299 cells,
we examined its function in p53-positive 3T3 fibroblasts. Silenc-
ing of Sesn1 with two different lentiviral-delivered shRNAs
increased p70S6K andS6 phosphorylation, indicatingmTOR ac-
tivation (Figure 6A). Furthermore, Sesn1 knockdown accelerated
the proliferation of these cells (Figure 6B).
p53 activation can downregulate mTOR signaling (Feng et al.,
2005; Horton et al., 2002). To examine the role of Sesn1 and
Sesn2 in this response, we silenced their expression in p53-neg-
ative H1299 cells and reinfected the silenced cells with GFP- or
Figure 5. Sesn2 Activates AMPK and Induces TSC2 Phosphorylation
(A) WT but not N-terminally truncated Sesn2 activates AMPK. HEK293 cells
were cotransfectedwith AMPKa1F expression vector alongwithGFP, Sesn2F,
and Sesn2F-DN expression vectors. After 48 hr, the cells were lysed, and
AMPKa1F immune complexes were isolated and assayed for their ability to
phosphorylate a TSC1:TSC2 complex isolated by immunoprecipitation from
lysates of transiently transfected HEK293 cells. The amounts of AMPKa1F,
Sesn2, and TSC2 in the kinase reactionwere examined by immunoblotting (IB).
(B) Sesn2 enhances TSC2 phosphorylation. HEK293 cells were cotransfected
with TSC1Myc and TSC2F expression vectors along with WT Sesn2F, N-ter-
minally truncated Sesn2F, or GFP expression vectors. After 48 hr, cells were
metabolically labeled with 32P-orthophosphate, and the TSC1:TSC2 complex
was immunoprecipitated 4 hr later, gel separated, and autoradiographed.
TSC2 and Sesn2 expression were examined by immunoblotting (IB).
(C) Sesn2-associated AMPKa is more extensively phosphorylated than AMPK
that is not associated with Sesn2. Sesn2F or GFP were induced by doxycy-
cline withdrawl in MCF7-tet cells. After 24 hr, cells were lysed, and the lysates
were subjected to immunoprecipitation with anti-Flag antibody. The superna-
tant of the immunoprecipitation reaction, the immune complexes, and the
total unfractionated lysate were examined for AMPKa phosphorylation and
content by immunoblotting.Figure 6. Sesn1 and Sesn2 Are Required for Negative Regulation
of mTOR under Basal and Stressed Conditions
(A) Sesn1 negatively regulates mTOR signaling in mouse fibroblasts. 3T3 cells
were infected with shLuciferase (shLuc)-, shSesn1-1-, or shSesn1-2-lentivi-
ruses, selected with puromycin, and analyzed 48 hr later for protein phosphor-
ylation (IB) and Sesn1 mRNA expression by northern blotting (NB). 18S RNA
was used to control for RNA loading.
(B) Cells (30,000) from (A) were plated onto 6-well plates and counted every
24 hr for 6 days.
(C) Sestrins are required for p53-induced mTOR inhibition. H1299 cells were
infected with shLuciferase (shLuc)-, shSesn1-, or shSesn2- lentiviruses and
48 hr later were infected with p53- or GFP-lentiviral vectors. After an additional
48 hr, the cells were lysed and analyzed by immunoblotting (IB) for p70S6K and
S6 phosphorylation and p53 and Sesn2 expression. Sesn1 expression was
examined by northern blotting (NB).
(D) Sesn1 and Sesn2 are required for downregulation of S6 phosphorylation in
Nutlin-3-treated cells. U2OS cells were infected with shLuciferase (shLuc)-,
shSesn1-, shSesn2-, or shp53-lentiviruses. After 48 hr, the cells were incu-
bated or not with Nutlin-3 (6 mM) for 12 hr as indicated to induce p53 accumu-
lation. Expression of p53, Sesn2, and p21Waf1 and S6 phosphorylation were
examined by immunoblotting (IB). Sesn1 mRNA was analyzed by northern
blotting (NB).
(E) Sesn2 and p53 are required for inhibition of mTOR signaling during camp-
tothecin-induced genotoxic stress. 3T3 cells of the indicated genotypes were
treatedwith camptothecin (Camp, 20 mM) for 12 hr, and protein expression and
phosphorylation were analyzed by immunoblotting.
(F) Sesn2 is required for DEN-induced inhibition of S6 phosphorylation in
mouse liver. Two-month-old Sesn2+/ and Sesn2/ male mice were injected
with DEN (100 mg/kg). After 24 hr, protein expression and phosphorylation in
liver homogenates were analyzed as above.Cell 134, 451–460, August 8, 2008 ª2008 Elsevier Inc. 455
p53-lentiviral vectors. As expected (Sablina et al., 2005), p53 in-
duced expression of both Sesn1 and Sesn2 (Figure 6C). Impor-
tantly, the ability of p53 to inhibit mTOR signaling, as measured
by p70S6K and S6 phosphorylation, was attenuated by silencing
of either Sesn1 or Sesn2 (Figure 6C). A similar abrogation of p53-
induced inhibition of S6 phosphorylation was observed upon
knockdown of either TSC2 or AMPKa1 (Figure S6B). To further
examine the role of Sesn1 and Sesn2 in p53-induced mTOR in-
hibition, we treated U2OS osteosarcoma cells, which contain
amplified MDM2, a negative regulator of p53 (Florenes et al.,
1994), with a specific inhibitor of theMDM2-p53 interaction, Nut-
lin-3 (Vassilev et al., 2004). Nutlin-3 induced p53 accumulation
and expression of p21Waf1, Sesn1, and Sesn2 and downregula-
tion of S6 phosphorylation (Figure 6D). Knockdown of Sesn1 and
to a lesser extent Sesn2 compromised the inhibition of S6 phos-
phorylation but had no effect on accumulation of p53 and induc-
tion of p21Waf1, both of which were abolished by p53 silencing,
which also prevented the inhibition of S6 phosphorylation.
Genotoxic stress can inhibit mTOR signaling through activa-
tion of p53 (Feng et al., 2005). To study the role of Sestrins in
this response in vivo, we generated Sesn2 knockout mice using
gene trap ES cells from Bay Genomics. The Sesn2-deficient ES
cells contain a pGT0Lxf expression vector with a strong splice
acceptor site integrated into the third intron of the mouse
Sesn2 gene, which results in expression of a truncated mRNA
and no Sesn2 protein (Figure S6C). Mice generated from these
cells were indeed Sesn2 null (Figures 6E and 6F). We treated
Sesn2+/, Sesn2/, and p53/ mouse embryo fibroblasts
(MEFs) immortalized by the 3T3 procedure with camptothecin,
a topoisomerase I inhibitor, to activate p53. Camptothecin treat-
ment inhibited p70S6K and S6 phosphorylation while enhancing
AMPK and ACC phosphorylation in Sesn2+/ cells but not in
Sesn2/ or p53 / cells (Figure 6E). Silencing of Sesn1 in
Sesn2+/ cells also compromised the inhibitory effect of campto-
thecin on mTOR (Figure S6D). Sesn2, however, had no effect on
activation of AMPK by AICAR (Figure S6E).
We treated 2-month-old Sesn2+/ and Sesn2/ mice with
DEN, which, upon metabolic activation in zone 3 hepatocytes,
becomes a potent alkylating agent (Buhler et al., 1992; Verna
et al., 1996) that causes p53 activation and induction of p53 tar-
get genes, such as Sesn1, Sesn2, and p21Waf1 (Figure S6F). DEN
also led to inhibition of S6 phosphorylation (Figure S6D), an
effect that was not seen in Sesn2/ mice (Figure 6G). Immuno-
histochemistry revealed that inhibition of S6 phosphorylation
was restricted to zone 3 hepatocytes, the main site of DEN met-
abolic activation (Figure S6G). This effect was much weaker in
Sesn2/ mice. Using hepatocyte-specific p53 knockout mice
created by crossing p53F/F mice (Jonkers et al., 2001) with
Alb-Cre mice (Postic et al., 1999), we confirmed that induction
of Sesn2 and p21Waf1 by DEN was p53 dependent (Figure S6H).
The Growth-Inhibitory Activity of Sestrins Is Mediated,
in Part, through Inhibition of mTOR Signaling
mTOR is a critical regulator of cell growth and proliferation
(Fingar et al., 2004; Wullschleger et al., 2006). To examine
whether Sestrins negatively regulate cell growth and prolifera-
tion, we expressed Sesn1 and Sesn2 in HEK293 cells and mea-
sured cell size and cell-cycle distribution. Either Sesn1 or Sesn2456 Cell 134, 451–460, August 8, 2008 ª2008 Elsevier Inc.decreased cell size (similar to the effect of rapamycin), especially
in G1 cells whose fraction was increased upon Sesn1 and Sesn2
expression (Figures 7A and 7B). To examine whether p53 regu-
lates cell size in a Sestrin-dependent manner, we infected
H1299 cells with shSesn2- or shLuc-lentiviruses and reinfected
the cells with either p53- or GFP-lentiviruses. p53 expression
decreased cell size, but this effect was abrogated in Sesn2-
silenced cells (Figure S7). We also found that Sesn2 truncation
mutants that were incapable of mTOR inhibition and AMPK acti-
vation (Figure S8A) failed to inhibit clonogenic growth of HEK293
cells, which was readily inhibited by WT Sesn1 or Sesn2
(Figure S8B). The redox-defective Sesn2(C125S) mutant also in-
hibited clonogenic growth, but not as effectively as WT Sesn2,
suggesting that some of the growth-inhibitory activity of Sesn2
may be redox dependent and mTOR independent. To examine
whether the Sestrin effect on cell size and proliferation is TSC2
dependent, we infected Tsc2+/+ and Tsc2/ cells with
a Sesn2- or GFP-lentiviruses and measured cell size and clono-
genic growth. Sesn2 expression decreased cell size and in-
hibited clonogenic growth of Tsc2+/+ but not Tsc2/ cells
(Figures 7C and 7D).
Ectopic Sesn2 expression inhibits cell growth and proliferation
(Budanov et al., 2002). To determine the role of mTOR in this
effect, we cotransfected MCF7 cells with Sesn2 or GFP expres-
sion vectors together with Rheb or H-Ras constructs. Sesn2
expression inhibited clonogenic growth by about 50%, and
coexpression of Rheb, but not H-Ras, attenuated this effect
(Figure 7E). In fact, H-Ras slightly potentiated the growth-inhib-
itory activity of Sesn2.
DISCUSSION
The mTOR signaling pathway is a central regulator of cell growth
and survival (Corradetti and Guan, 2006; Fingar and Blenis,
2004; Guertin and Sabatini, 2005; Hay and Sonenberg, 2004;
Soliman, 2005; Thomas, 2006; Wullschleger et al., 2006). It is
therefore not surprising that adverse environmental conditions
negatively regulate cell growth by inhibiting mTOR (Corradetti
and Guan, 2006). In addition to nutrient limitation, mTOR activity
is negatively regulated by genotoxic stress and hypoxia, condi-
tions that activate tumor suppressor p53. The ability of p53 to
inhibit mTOR signaling is in line with its function as a negative
regulator of cell growth and proliferation (Levine et al., 2006).
The results described above strongly suggest that the ability of
p53 to inhibit mTOR signaling depends on two of its target
genes: Sesn1 and Sesn2.
The Sestrins belong to a small and evolutionary conserved
family composed of three members in mammals, of which
Sesn1 and Sesn2 are stress inducible and p53 regulated
(Budanov et al., 2002; Velasco-Miguel et al., 1999). The ability
of Sesn1 and Sesn2 to inhibit cell growth and proliferation was
attributed to their redox activity (Budanov et al., 2004). The pres-
ent work, however, demonstrates that Sesn1 and Sesn2 are po-
tent inhibitors of mTOR signaling, acting in a manner that does
not depend on their redox activity, which only makes a partial
contribution to their growth-inhibitory activity. Sesn1 and
Sesn2 inhibit mTORC1 activity toward p70S6K and 4E-BP1 in
a variety of human andmouse cell lines, as well as in mouse liver.
Figure 7. Sestrins Inhibit Cell Growth and
Proliferation via mTOR
(A and B) Sesn1 and Sesn2 expression decreases
cell size and inhibits cell proliferation at G1.
HEK293 cells were infected with Sesn1-, Sesn2-,
or GFP-lentiviruses. After 48 hr, cell size (A) and
cell-cycle distribution (B) were analyzed by flow
cytometry.
(C and D) Sesn2 expression decreases cell size
and inhibits clonogenic growth in Tsc2+/+ but not
Tsc2/ cells. Tsc2+/+ and Tsc2/ cells were
infected with Sesn2- or GFP-lentiviruses. After
48 hr, cell size (C) was analyzed by flow cytometry.
Colony formation (D) was analyzed 14 days after
infection.
(E) Sesn2 inhibits clonogenic growth upstream to
Rheb. MCF7 cells were transfected with Sesn2
or GFP expression vectors along with Rheb,
H-Ras, or an empty expression vector. The cells
were selected in puromycin-containing medium
and colony formation was quantitated after 3
weeks.
(F) A model explaining our results. Sesn1 and
Sesn2 are induced upon stress-triggered p53 ac-
tivation. Sesn1 and Sesn2 dimers interact with
TSC1:TSC2 and AMPKa and activate AMPK by in-
duced proximity-dependent autophosphorylation.
This results in TSC2 phosphorylation and stimula-
tion of its GAP activity, leading to inhibition of
mTOR signaling, which is positively regulated by
growth factors via Ras and PI3K.
Results in (A)–(E) are averages ± SE. * indicates
p% 0.05 by Student’s t test.Notably, the ability of the hepatocarcinogen DEN to inhibit S6
phosphorylation is restricted to zone 3 hepatocytes, which are
the main site in which it undergoes metabolic activation to be-
come a potent alkylating agent (Buhler et al., 1992), and this in-
hibitory activity is Sesn2 dependent. By inhibiting 4E-BP1 phos-
phorylation, Sesn2 enhances its interaction with eIF-4E and
inhibits expression of growth regulatory proteins, such as cyclin
D1 and c-Myc, whose translation is eIF-4E dependent and sen-
sitive to 4E-BP1 phosphorylation (Averous et al., 2007; Averous
and Proud, 2006; Mamane et al., 2004).
The Sestrins impact mTORC1 activity through the
TSC1:TSC2 complex. Being a GAP for Rheb, the direct activa-
tor of mTORC1, the TSC1:TSC2 complex is a central regulator
of mTOR signaling (Corradetti and Guan, 2006; Kwiatkowski
and Manning, 2005). Sesn2 expression decreases Rheb GTP
loading, and the ability of both Sesn1 and Sesn2 to inhibit
mTOR signaling is TSC2 dependent. One way to regulate
TSC1:TSC2 GAP activity is through TSC2 phosphorylation,
but other modes of regulation may also exist (Corradetti and
Guan, 2006). Although the Sestrins have no effect on ERK
and its target RSK or GSK3b, which can serve as TSC2
kinases, they stimulate the activity of AMPK, a major TSC2kinase (Corradetti and Guan, 2006). Furthermore, Sestrin
expression enhanced TSC2 phosphorylation in live cells, and
this effect required the N terminus of Sesn2, which mediates
AMPKa binding. Sesn2 did not stimulate TSC1 phosphoryla-
tion, and Sesn2-activated AMPK did not phosphorylate TSC1.
Importantly, the mTOR inhibitory activity of Sesn1 and Sesn2
depends on AMPKa, whose phosphorylation at the activation
loop was enhanced upon Sestrin expression. Inhibition of
AMPK with compound C as well as shRNA silencing of AMPKa1
attenuated the ability of Sesn2 to inhibit mTOR signaling. Coim-
munoprecipitation and gel filtration analyses revealed an interac-
tion between Sesn2 and AMPKa, suggesting that Sestrins are
engaged in formation of a large protein complex containing
AMPK and TSC1:TSC2. We propose that Sesn1 and Sesn2
induction in response to genotoxic stress results in binding of
Sestrins, most likely as dimers (data not shown), to AMPK and
TSC1:TSC2, as well as autoactivation of AMPK through a
mechanism based on induced proximity. In addition to activation
of AMPK, the Sestrins recruit it to phosphorylate TSC2
(Figure 7F). Phosphorylation of TSC2 correlates with enhance-
ment of its GAP activity that leads to inhibition of Rheb
and mTOR.Cell 134, 451–460, August 8, 2008 ª2008 Elsevier Inc. 457
Importantly, we obtained ample and clear evidence that Sesn1
and Sesn2 are critical mediators of p53’s ability to inhibit mTOR
signaling. Using shRNA-mediated silencing, we found that both
Sesn1 and Sesn2 participate in mTOR inhibition upon p53 acti-
vation in human cancer cells. Furthermore, disruption of the
Sesn2 gene in mice attenuated the inhibition of p70S6K activity
by the DNA-damaging agents: camptothecin in fibroblasts and
DEN in hepatocytes. In both cases, inhibition of p70S6K was
p53 mediated, but unlike the p53 deficiency, the absence of
Sesn2 has no effect on induction of p21Waf1, another p53 target
gene. Thus, Sesn2 (and presumably Sesn1) seems to mediate
only one aspect of p53 signaling—inhibition of mTOR. Corre-
spondingly, the growth-inhibitory activity of Sesn2 is not as
strong as that of p53, which has additional targets with anti-
proliferative activity, such as p21Waf1.
p53 deficiency and activation of mTOR signaling are hallmarks
of human cancer (Levine, 1997; Sabatini, 2006; Thomas, 2006).
Several mechanisms account for mTOR activation in cancer,
including activation of Ras, PI3K, and AKT and inactivation of
tumor suppressors that negatively regulate these molecules:
PTEN, TSC1, TSC2, and LKB1 (Corradetti and Guan, 2006;
Sabatini, 2006; Thomas, 2006). Although p53 can induce expres-
sion of several negative regulators of mTOR, including PTEN,
TSC2, AMPKb1, and IGF-BP3, in a cell type-dependent manner
(Feng et al., 2007), our results demonstrate that p53-mediated
inhibition of mTOR depends mainly on Sesn1 and Sesn2 in
mouse fibroblasts and certain human cancer cell lines and on
Sesn2 in mouse liver.
Inhibition of mTOR suppresses cell growth and proliferation
(Fingar et al., 2004; Wullschleger et al., 2006). Sesn2 was known
to inhibit cell proliferation (Budanov et al., 2002), but its mecha-
nism of action was heretofore unknown. Our results strongly
suggest that Sesn1 and Sesn2 exert their growth-inhibitory
effect via mTOR and may cooperate with other antiproliferative
p53 targets, such as p21Waf1. Interestingly, the SESN1 (6q21)
and SESN2 (1p35) loci are frequently deleted in a variety of hu-
man cancers (Velasco-Miguel et al., 1999; Ragnarsson et al.,
1999; Schwab et al., 1996), suggesting that they harbor one or
more tumor suppressors. We found that Sesn2 deficiency ren-
ders murine fibroblasts more susceptible to oncogenic transfor-
mation, and this effect may depend on mTOR inhibition
(Figure S9). Hence, SESN1 and SESN2may indeed be important
components of the tumor-suppressor network activated by p53.
In summary, although more remains to be learned about Ses-
trin biology and mechanism of action, our results establish these
proteins as critical links between p53 and mTOR that enable p53
to inhibit cell growth.
EXPERIMENTAL PROCEDURES
Mice
Sesn2/ mice on a mixed C57BL/129 background were generated from ES
cells obtained from Bay Genomics. These cells were created by a random
gene trap approach and contain a pGT0Lxf construct within exon 3 of the
Sesn2 gene with a strong splice acceptor site expressing a b-gal-Neo fusion
protein that disrupts the Sesn2ORF. p53Dhepmicewere generated by crossing
of p53F/F mice on a mixed FVB/129 (Jonkers et al., 2001) with Alb-Cre mice
(Postic et al., 1999) on a C57BL6 background for at least five generations.
Efficient and specific deletion of p53 in hepatocytes was confirmed by PCR458 Cell 134, 451–460, August 8, 2008 ª2008 Elsevier Inc.analysis. All mice were maintained in filter topped cages on autoclaved food
and water at University of California, San Diego (UCSD) according to National
Institutes of Health guidelines.
Cell Culture, Transfection, Infection, and Treatment
Tsc2+/+ and Tsc2/ 3T3 fibroblasts were a gift from D. Kwiatkowsky. MCF7-
tet OFF cells were fromClontech. Sesn2+/ and Sesn2/ 3T3 fibroblasts were
derived via the 3T3 protocol fromMEFs. All cells were cultured in high-glucose
DMEM supplemented with 10% FCS, L-glutamine, penicillin, and streptomy-
cin. For the MCF7-tet OFF system, doxycycline was added at 0.5 mg/ml. Lip-
ofectamine-Plus (Invitrogen) was used as a transfection reagent. Infection with
retroviral vectors was described (Budanov et al., 2004; Budanov et al., 2002).
For rapamycin treatment, cells were usually incubated with 20 ng/ml rapamy-
cin. For camptothecin treatment, cells were incubated 12 hr after plating with
camptothecin (20 mM) for 12 hr more. For Nutlin-3 treatment, cells were incu-
bated with 6 mM of Nutlin-3. For insulin and IGF1 treatment, cells were kept in
serum-free DMEM for 12 hr and incubated with the growth factors for 1 hr. For
colony formation assays, cells were transfected with the different plasmids as
described (Budanov et al., 2002), cultured for 14–21 days under selective pres-
sure, fixed, and stained with methylene blue.
Metabolic Labeling
HEK293 cells were transfected with TSC1-Myc plus TSC2-Flag along with
GFP, WT, or N-terminally trancated Sesn2 expression vectors. After 48 hr,
the growth medium was replaced with phosphate-free DMEM supplemented
with dialysed serum and 1 mCi of orthophosphate. After 4 hr, cells were lysed,
and the TSC1:TSC2 complex was immunoprecipitated with anti-Flag anti-
body.
AMPK Kinase Assay
HEK293 cells were cotransfected with AMPKa1-Flag along with GFP, WT or
N-terminally truncated Sesn2 expression vectors. After 48 hr, the cells were
lysed, and AMPKa1F was immunoprecipitated with anti-Flag agarose (Sigma).
Kinase activity was examined in AMPK reaction buffer (20 mM HEPES-NaOH
[pH 7.5], 0.4 mM dithiotriethol, 18 mMMgCl2, 125 mM unlabeled ATP, 6 mM b-
glycerophosphate, 1 mM EGTA, and 0.25 mM Na3VO4) containing 5 mCi
[g-32P]ATP.
Cell Lysis, Immunoprecipitation, and Immunoblot Analyses
For ordinary immunoblot analysis, cells were lysed in RIPA-SDS buffer (Buda-
nov et al., 2002). For immunoprecipitation analysis, cells or livers were lysed in
NP40 buffer (20 mM Tris-HCl, 5% glycerol, 138 mM NaCl, 2.7 mM KCl, 1%
NP40, 20 mM NaF, 18 mM pepstatin, 5 mM EDTA, 1 mM Na3VO4, 20 mM leu-
peptin, 2.5 mM Na pyrophosphate, and 1 mM b-glycerophosphate). Cell
lysates were incubated with the indicated antibodies for 1 hr, and incubation
with a 1:1 mixture of protein A- and protein G-Sepharose beads followed.
For Cap-binding assay, cell lysates were incubated with m7G-RNA-Sepharose
beads (Amersham) for 6 hr. After centrifugation, the beads were washed four
times in lysis buffer. Total and immunoprecipitated proteins were resolved
by SDS-PAGE, transferred onto polyvinylidene fluoride membranes, and
probed with the relevant antibodies (Budanov et al., 2004).
Analysis of Rheb GTP/GDP Content
Cells were metabolically labeled with 32P-orthophosphate and immunoprecip-
itated with anti-Rheb antibody (Santa Cruz, CA), and guanine nucleotides were
extracted and resolved by thin-layer chromatography (Garami et al., 2003).
Gel Filtration Analysis
Gel Filtration analysis was performed on a Superdex 200 column (Amersham
Pharmacia Biotech) with a fast-flow liquid chromatography system. The col-
umn buffer was PBS. The column was calibrated with protein markers ranging
from 29 to 2000 kDa (Sigma).
SUPPLEMENTAL DATA
Supplemental Data include eight figures, Supplemental Experimental Proce-
dures, and Supplemental References and can be found with this article online
at http://www.cell.com/cgi/content/full/134/3/451/DC1/.
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